P252 THE TREATMENT WITH BETA–BLOCKERS AFTER MYOCARDIAL INFARCTION WITHOUT REDUCED EJECTION FRACTION (REBOOT) TRIAL, 2023 UPDATES

Abstract Introduction The role of beta blockers (BB) post–myocardial infarction (MI) in patients without reduced ejection fraction the era invasive management is controversial results from observational studies have led to opposite results. Methods REBOOT an independent multinational pragmatic, controlled, randomized, open–label, with blinded endpoint adjudication clinical trial. study testing benefits BB maintenance therapy post–MI (either or ST segment elevation) discharged LVEF >40%. Patients ≥18 years old undergoing during admission and history heart failure (HF) are eligible participate. At discharge, they 1:1 randomized either receive (agent dose chosen by treating physician) no therapy. primary a composite all–cause death, nonfatal re–MI, hospitalization over minimum follow–up period 2.75 (minimum 2 years, maximum 3 years). Events adjudicated committee. Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) sponsor trial coordinator Spanish Centers while Istituto di Ricerche Farmacologiche Mario Negri IRCCS coordinates Italian participating network. Hospital for COVID–19 were also recorded since June 2020. Results currently ongoing 29 centers still actively recruiting. A sample size 8468 pts (728 events) was estimated provide power 85% detect RRR 20% (incidence control 10%) assuming 5% withdrawals. More than 75 35 recruited patients. first been included Spain October 2018, Italy January 2019. On December 31st 2022, number enrolled 1685. top three enrollers at moment are: Ospedale G. da Saliceto –Piacenza (483 pts), S. Luigi Gonzaga – Orbassano (183 pts) A.O San’Anna San Sebastiano Caserta (170 pts). patient enrollment rate almost stable all periods slight decrease COVID pandemic outbreaks. Network goal include 1800 April 2023. will become available end 2025. Conclusion REBOOT, other trials, robust evidence guide prescription after MI LVEF.